Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Gynecological Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1412660

Anlotinib inhibits cervical cancer cell proliferation and invasion by suppressing cytokine secretion in activated cancer-associated fibroblasts

Provisionally accepted
Yaozu Xiong Yaozu Xiong 1*Xiaoting Xu Xiaoting Xu 2Xilei Zhou Xilei Zhou 1Yu Suo Tong Yu Suo Tong 1Yu C. Hua Yu C. Hua 1*
  • 1 Huai'an First People's Hospital, Huai'an, China
  • 2 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Objective:The aim of this study was to investigate whether anlotinib could exert an inhibitory effect on the proliferation and invasion of cervical cancer cells by inhibiting cytokines secreted by activated cancer-associated fibroblasts (CAFs).Methods:CAFs were isolated from cervical cancer tissues and experimentally studied in vivo and in vitro. Molecular biology experimental methods were used to verify whether anlotinib could inhibit the pro-carcinogenic effects of CAFs derived from cervical cancer tissues.Results:CAFs promote the proliferation and invasion of cervical cancer cells.CAFs and suppressed the release of interleukin (IL)-6 (IL-6) and IL-8. In vivo studies have shown that anlotinib diminished the growth of xenografted cervical cancer cells, and treatment in combination with docetaxel had an even more significant tumor growth inhibitory effect.Conclusions:Anlotinib inhibits the pro-cancer effects of CAFs by suppressing the activation of CAFs and the secretion of pro-cancer cytokines. Our findings suggest that the combination of anlotinib and docetaxel may be a potential strategy for the treatment of refractory cervical cancer.

    Keywords: CAFs, Anlotinib, cervical cancer, IL-6, IL-8

    Received: 05 Apr 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Xiong, Xu, Zhou, Tong and Hua. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yaozu Xiong, Huai'an First People's Hospital, Huai'an, China
    Yu C. Hua, Huai'an First People's Hospital, Huai'an, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.